Consolidated Planning Corp Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Consolidated Planning Corp grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.0% during the 4th quarter, HoldingsChannel reports. The fund owned 8,008 shares of the medical research company’s stock after purchasing an additional 660 shares during the period. Consolidated Planning Corp’s holdings in IQVIA were worth $1,853,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in IQV. AdvisorNet Financial Inc grew its stake in IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at about $32,000. Activest Wealth Management purchased a new stake in IQVIA in the fourth quarter worth about $35,000. CVA Family Office LLC bought a new position in IQVIA during the 4th quarter worth about $43,000. Finally, CoreFirst Bank & Trust bought a new stake in shares of IQVIA in the 3rd quarter valued at about $44,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV traded up $0.90 during mid-day trading on Friday, hitting $234.88. The company’s stock had a trading volume of 697,640 shares, compared to its average volume of 761,918. The business’s fifty day moving average is $245.28 and its two-hundred day moving average is $223.02. The stock has a market cap of $42.63 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 2.26 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.54 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. SVB Leerink began coverage on shares of IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Evercore ISI lifted their price target on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. UBS Group raised their price objective on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, BTIG Research started coverage on shares of IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.